- Trials with a EudraCT protocol (83)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
83 result(s) found for: Induced ovulation.
Displaying page 1 of 5.
EudraCT Number: 2012-005571-14 | Sponsor Protocol Number: TIMING | Start Date*: 2013-08-02 |
Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE | ||
Full Title: CLINICAL TRIAL, SINGLE BLIND, RANDOMIZED, CONTROLLED PROSPECTIVE EVALUATION FOR OPTIMUM TIME INTERVAL BETWEEN ACETATE ADMINISTRATION AND PUNCTURE TRIPTORELIN FOLLICULAR IN IVF TREATMENT | ||
Medical condition: INFERTILITY | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-007932-25 | Sponsor Protocol Number: 28091 | Start Date*: 2008-05-07 |
Sponsor Name:Merck Lipha Santé | ||
Full Title: A phase IIIb randomized open-label study to compare between IVF/ICSI outcomes two regimen of Cetrotide 0.25 mg used from Day 1 or from Day 7 of the menstrual cycle (Day 0 or Day 6 of stimulation) ... | ||
Medical condition: Prevention of premature ovulation in polycystic ovarian women undergoing a controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-003092-18 | Sponsor Protocol Number: TIKTAC | Start Date*: 2021-05-12 |
Sponsor Name:Medical University Innsbruck | ||
Full Title: Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure - “Time Is Kidney in the Treatment of myelomA Cast n... | ||
Medical condition: Multiple Myeloma: cohort 1: dialysis dependent patients; cohort 2: patients not dialysis dependent | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002258-10 | Sponsor Protocol Number: IBRB-02 | Start Date*: 2016-10-19 | |||||||||||
Sponsor Name:Dermal Laboratories Ltd | |||||||||||||
Full Title: SINCERE: A single-centre, assessor blind, randomised pilot study to evaluate the safety, tolerability and acceptability of RB Lotion compared to standard-of-care for Radiation Induced Skin Reaction... | |||||||||||||
Medical condition: Radiation Induced Skin Reactions (RISR) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003725-22 | Sponsor Protocol Number: KKS-306 | Start Date*: 2023-04-20 | |||||||||||||||||||||
Sponsor Name:Justus-Liebig-University Gießen | |||||||||||||||||||||||
Full Title: Acute effect of iloprost (Ventavis®) inhalation in patients with exercise-induced pulmonary hypertension after a COVID-19 infection | |||||||||||||||||||||||
Medical condition: Exercise-induced pulmonary hypertension after a COVID-19 infection | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-004207-32 | Sponsor Protocol Number: TIKTAC-2-Trial | Start Date*: 2023-04-20 |
Sponsor Name:Medical University Innsbruck, Internal Medicine V | ||
Full Title: Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure NOT requiring dialysis - “Time Is Kidney in the Trea... | ||
Medical condition: Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Patients with renal failure have a poor prognosis. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002911-33 | Sponsor Protocol Number: ABT-gpASIT011 | Start Date*: 2018-12-18 | |||||||||||
Sponsor Name:ASIT biotech S.A. | |||||||||||||
Full Title: A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+™ in patients with grass p... | |||||||||||||
Medical condition: Treatment of seasonal grass pollen-induced rhinoconjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BE (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002046-31 | Sponsor Protocol Number: KFL3503 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:Mundipharma Research Limited | |||||||||||||
Full Title: A randomised, single blind, cross-over study to compare a fixed dose combination of fluticasone propionate / formoterol fumarate (fluticasone /formoterol breath actuated inhaler (BAI)) with a fixe... | |||||||||||||
Medical condition: Fixed airflow obstruction with elevated eosinophils | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Prematurely Ended) ES (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005576-35 | Sponsor Protocol Number: CP-PRO-CoVLP-021 | Start Date*: 2021-05-06 | |||||||||||
Sponsor Name:Medicago R&D Inc. | |||||||||||||
Full Title: A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years o... | |||||||||||||
Medical condition: Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000187-15 | Sponsor Protocol Number: MK-8616-145 | Start Date*: 2017-09-18 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecu... | |||||||||||||
Medical condition: Reversal of neuromuscular blockade | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002056-20 | Sponsor Protocol Number: APHP200495 | Start Date*: 2020-10-14 |
Sponsor Name:Assistance Publique -Hôpitaux de Paris | ||
Full Title: FX06 to rescue acute respiratory distress syndrome during Covid-19 pneumonia : FX-COVID | ||
Medical condition: Patients admitted in participating ICUs who received mechanical ventilation for SARS-CoV-2 induced acute respiratory distress syndrome (ARDS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-006004-16 | Sponsor Protocol Number: 03PDE2020 | Start Date*: 2021-07-16 |
Sponsor Name:Celon Pharma S.A. | ||
Full Title: Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A inhibitor) in Patients with Parkinson's Diseas... | ||
Medical condition: Levodopa-induced dyskinesia in Parkinson's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003060-40 | Sponsor Protocol Number: TICSI | Start Date*: 2017-01-17 | |||||||||||
Sponsor Name:University of Oxford, Clinical Trials and Research Governance | |||||||||||||
Full Title: Targeting Iatrogenic Cushing’s Syndrome with 11β-hydroxysteroid dehydrogenase type 1 Inhibition | |||||||||||||
Medical condition: Adverse effects of prescribed glucocorticoid therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003370-26 | Sponsor Protocol Number: CLAF237ADE03 | Start Date*: 2007-11-15 |
Sponsor Name:Charite Universitätsmedizin Berlin | ||
Full Title: A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man | ||
Medical condition: This is a single center, randomized, double-blind pilot study on patients with Type 2 diabetes. The purpose of this study is to test the effects of vildagliptin (as add-on to metformin) on hepatic ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003381-21 | Sponsor Protocol Number: RAFAEL | Start Date*: 2023-09-11 |
Sponsor Name:Psyon, s.r.o. | ||
Full Title: Regression of atherosclerosis induced by life changing experience with psilocybin | ||
Medical condition: Ischemic Heart Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002483-11 | Sponsor Protocol Number: 18HH4626 | Start Date*: 2019-05-15 | ||||||||||||||||
Sponsor Name:Imperial College London | ||||||||||||||||||
Full Title: CHOlesterol Reduction with Evolocumab and coronAry microvascuLar function: The CHORAL Flow Study | ||||||||||||||||||
Medical condition: Coronary artery disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002781-31 | Sponsor Protocol Number: PQBirch301 | Start Date*: 2017-02-16 | |||||||||||
Sponsor Name:Allergy Therapeutics (UK) Ltd | |||||||||||||
Full Title: A multi-centre, double-blind, randomised, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Birch Modified Allergen Tyrosine adsorbed + MPL in the prevention of season... | |||||||||||||
Medical condition: Seasonal allergic rhinoconjunctivitis due to birch pollen | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001301-40 | Sponsor Protocol Number: VAC059 | Start Date*: 2014-07-31 |
Sponsor Name:University of Oxford | ||
Full Title: A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Concomitant Administration of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01¬B + ChAd63 and... | ||
Medical condition: Plasmodium falciparum infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-004163-12 | Sponsor Protocol Number: RP2017-001 | Start Date*: 2018-01-28 | |||||||||||
Sponsor Name:ReposPharma | |||||||||||||
Full Title: A phase 2a TDM-guided clinical study on the safety and efficacy of mebendazole in patients with advanced gastrointestinal cancer or cancer of unknown origin | |||||||||||||
Medical condition: Squamous cell cancer or adenocarcinoma, including primary cancer of the liver, of the gastrointestinal tract or cancer of unknown origin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006053-22 | Sponsor Protocol Number: NLX-112-DYS-101 | Start Date*: 2021-09-22 |
Sponsor Name:Neurolixis SAS | ||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson’s Disease | ||
Medical condition: Parkinson´s disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
